Dynavax rises after its shingles vaccine shows similar immune response to GSK's shot in study

Shares of vaccine developer Dynavax DVAX.O rise 9.3% to $11.40

Co says its experimental shingles vaccine generated a similar immune response as GSK's GSK.L blockbuster shot Shingrix and a better safety profile in a early-to-mid stage study

Dynavax tested two variants of its candidate, Z-1018, in a trial of 92 people aged 50 through 69 years; all subjects injected with either of the vaccine variants showed a similar immune response to those given Shingrix, one month after the second dose- co says

Co says it plans to begin the second part of the trial with one of the doses by the second half of the year in adults 70 years of age and older

Shingles, or herpes zosteris, is a viral infection that causes painful rashes

Up to last close, DVAX was down 18.4% YTD